Primary and Secondary Prevention in Mixed Dyslipidemia: What Do the Guidelines Say? CME/CE

Author Information and Disclosures

Release Date: May 30, 2008; Valid for credit through May 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 nursing contact hours (1.0 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
GlaxoSmithKline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Recognize the importance of extending beyond the target of LDL-C to also include elevated levels of non-HDL-C and triglycerides as independent risk factors for CVD
  2. Discuss new treatment options in triglyceride management resulting in advances in their application and utility.
  3. Review the safety and efficacy of available therapies for mixed dyslipidemia.
  4. Identify patients who are candidates for combination lipid-modifying therapies.
  5. Apply evidence-based data and practice guidelines to real-world medical practice for reducing cardiovascular disease risk.
Authors and Disclosures

Michael Miller, MD, FACC, FAHA
Disclosure: Michael Miller, MD, has disclosed that he has received grants for clinical research from Sanofi-Aventis and Merck/Schering-Plough. Dr. Miller has also disclosed that he has received grants for educational activities from AstraZeneca, Pfizer, and Merck/Schering-Plough.


David Danar, MD
Disclosure: David Danar has disclosed that he owns a small quantity of Pfizer Inc stock.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-019-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.